1. Home
  2. ENTX vs CIK Comparison

ENTX vs CIK Comparison

Compare ENTX & CIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

SELL

Current Price

$2.50

Market Cap

147.4M

Sector

Health Care

ML Signal

SELL

Logo Credit Suisse Asset Management Income Fund Inc.

CIK

Credit Suisse Asset Management Income Fund Inc.

SELL

Current Price

$2.30

Market Cap

127.8M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
ENTX
CIK
Founded
2010
N/A
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
147.4M
127.8M
IPO Year
2015
1995

Fundamental Metrics

Financial Performance
Metric
ENTX
CIK
Price
$2.50
$2.30
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
★ $9.75
N/A
AVG Volume (30 Days)
554.8K
★ 588.5K
Earning Date
11-13-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ 0.22
N/A
Revenue
★ $42,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$11.32
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.91
$2.29
52 Week High
$4.20
$2.90

Technical Indicators

Market Signals
Indicator
ENTX
CIK
Relative Strength Index (RSI) 38.67 36.20
Support Level $1.46 N/A
Resistance Level $3.08 $2.40
Average True Range (ATR) 0.18 0.03
MACD -0.03 0.00
Stochastic Oscillator 11.50 9.06

Price Performance

Historical Comparison
ENTX
CIK

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

About CIK Credit Suisse Asset Management Income Fund Inc.

Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. UBS Asset Management serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.

Share on Social Networks: